- Home
- SER vs BOLD Comparison
SER vs BOLD Comparison
Compare SER & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- BOLD
- Stock Information
- Founded
- SER 2017
- BOLD 2018
- Country
- SER United States
- BOLD United States
- Employees
- SER N/A
- BOLD N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- SER Health Care
- BOLD
- Exchange
- SER Nasdaq
- BOLD Nasdaq
- Market Cap
- SER 46.7M
- BOLD 54.9M
- IPO Year
- SER 2018
- BOLD 2024
- Fundamental
- Price
- SER $6.13
- BOLD $2.50
- Analyst Decision
- SER
- BOLD Buy
- Analyst Count
- SER 0
- BOLD 3
- Target Price
- SER N/A
- BOLD $22.50
- AVG Volume (30 Days)
- SER 37.9K
- BOLD 103.1K
- Earning Date
- SER 11-12-2024
- BOLD 11-07-2024
- Dividend Yield
- SER N/A
- BOLD N/A
- EPS Growth
- SER N/A
- BOLD N/A
- EPS
- SER N/A
- BOLD N/A
- Revenue
- SER $3,157,500.00
- BOLD N/A
- Revenue This Year
- SER N/A
- BOLD N/A
- Revenue Next Year
- SER N/A
- BOLD N/A
- P/E Ratio
- SER N/A
- BOLD N/A
- Revenue Growth
- SER 2454.55
- BOLD N/A
- 52 Week Low
- SER $3.81
- BOLD $2.33
- 52 Week High
- SER $23.18
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- SER 58.82
- BOLD N/A
- Support Level
- SER $4.15
- BOLD N/A
- Resistance Level
- SER $6.24
- BOLD N/A
- Average True Range (ATR)
- SER 0.73
- BOLD 0.00
- MACD
- SER 0.08
- BOLD 0.00
- Stochastic Oscillator
- SER 84.62
- BOLD 0.00
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.